Physician profile
Jared M Johnson
NPI 1699425413
$569.19
in general payments reported to CMS, 2019-2025
12 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $203 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $139.07 | 2023-2025 | Andexxa, Airsupra, Lokelma |
| Baxter Healthcare | $97.13 | 2023 | |
| Lilly USA, LLC | $88.26 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $60.09 | 2023-2024 | Zerbaxa, Dificid, Pifeltro |
| Bayer Healthcare Pharmaceuticals INC. | $35.02 | 2025 | |
| Sumitomo Pharma America, INC. | $30.39 | 2025 | Gemtesa |
| United Therapeutics Corporation | $26.53 | 2024 | Tyvaso |
| Genzyme Corporation | $24.56 | 2023 | |
| Abbvie INC. | $20.03 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2024 | Ofev |
| Novo Nordisk INC | $15.08 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $14.86 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.